Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21664479 | 0.93 | ALDH1A1 (0.37) | ALDH1A1KDM4ELTA4HMEN1KMT2A | |
| SCHEMBL15495130 | 0.87 | ALDH1A1 (0.50) | ALDH1A1KDM4ELTA4HMEN1KMT2A | |
| SCHEMBL14041545 | 0.86 | HRH3 (0.45) | ALDH1A1KDM4EMEN1KMT2AUSP2 | |
| SCHEMBL21907048 | 0.83 | ALDH1A1 (0.44) | ALDH1A1KDM4ELTA4HMEN1KMT2A | |
| SCHEMBL16622424 | 0.83 | HSD11B1 (0.41) | ALDH1A1KDM4EMEN1KMT2ANPC1 | |
| SCHEMBL20331332 | 0.82 | ALDH1A1 (0.49) | ALDH1A1KDM4EMEN1KMT2AUSP2 | |
| SCHEMBL26445641 | 0.79 | DAO (0.40) | HRH3NPC1DRD3 | |
| SCHEMBL25864036 | 0.79 | — | — | |
| SCHEMBL2512123 | 0.79 | ALDH1A1 (0.55) | ALDH1A1KDM4ELTA4HMEN1KMT2A | |
| SCHEMBL22964563 | 0.78 | KDM4E (0.32) | KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024054766-A2 | MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | MITO BIOPHARMA, LLC (US) | 2024-03-14 | — | — | WO | disclosed |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-3848363-B1 | TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND | MEDSHINE DISCOVERY INC (CN) | 2023-07-19 | — | — | EP | disclosed |
| US-20230151136-A1 | CATALYST COMPOSITION FOR POLYURETHANES | MOMENTIVE PERFORMANCE MATERIALS INC. | 2023-05-18 | — | — | US | disclosed |
| US-20210292313-A1 | SUBSTITUTED PHENAZINES AND METHODS OF TREATING CANCER AND BACTERIAL DISEASES | Rongved, Pål (NO) | 2021-09-23 | — | — | US | disclosed |
| EP-3848363-A1 | TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND | Medshine Discovery Inc. (CN) | 2021-07-14 | — | — | EP | disclosed |
| EP-3543227-B1 | FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD (CN) | 2020-12-30 | — | — | EP | disclosed |
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200155689-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2020-05-21 | — | — | US | disclosed |
| EP-3543227-A1 | FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Guangdong Zhongsheng Pharmaceutical Co., Ltd (CN) | 2019-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292313-A1 | SUBSTITUTED PHENAZINES AND METHODS OF TREATING CANCER AND BACTERIAL DISEASES | TLR5, TOP2A, SCN5A | ALDH1A1 2277/4885KDM4E 1515/4885LTA4H 3545/4885 |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | ALDH1A1 4021/4885KDM4E 1434/4885LTA4H 3770/4885 |
| US-20200155689-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | ALDH1A1 3671/4885KDM4E 1613/4885LTA4H 3535/4885 |
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | ALDH1A1 2833/4885KDM4E 3116/4885LTA4H 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.